Journal of Human Genetics and Genomics

Published by: Kowsar

The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection

Mahboubeh Hajiabdolbaghi 1 , Reza Shahsiah 2 , Mahsa Motavaf 3 and Tabasom Zavari 1 , *
Authors Information
1 Department of Infectious Disease, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Pathology, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Molecular Genetics, Tarbiat Modares University, Tehran, IR ran
Article information
  • Journal of Human Genetics and Genomics: April 2017, 1 (1); e65255
  • Published Online: April 25, 2017
  • Article Type: Research Article
  • Received: February 2, 2017
  • Revised: March 12, 2017
  • Accepted: April 2, 2017
  • DOI: 10.5812/jhgg.65255

How to Cite: Hajiabdolbaghi M, Shahsiah R, Motavaf M, Zavari T. The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection, J Human Gen Genom. 2017 ; 1(1):e65255. doi: 10.5812/jhgg.65255.

Copyright © 2017, Journal of Human Genetics and Genomics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10(5):681-701. doi: 10.1007/s12072-016-9736-3. [PubMed: 27229718].
  • 2. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259. [PubMed: 25069599].
  • 3. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011;31(s1):45-52.
  • 4. Alter HJ, Liang TJ. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med. 2012;156(4):317-8. doi: 10.7326/0003-4819-156-4-201202210-00014. [PubMed: 22351718].
  • 5. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-9. doi: 10.1038/ng.449. [PubMed: 19749757].
  • 6. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100-4. doi: 10.1038/ng.447. [PubMed: 19749758].
  • 7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401. doi: 10.1038/nature08309. [PubMed: 19684573].
  • 8. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010;14:e113-6.
  • 9. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012;12(12). doi: 10.5812/hepatmon.8387.
  • 10. Mahboobi N, Behnava B, Alavian SM. IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report. Hepat Mon. 2011;11(5):386-8. [PubMed: 22087170].
  • 11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82. doi: 10.1056/NEJMoa020047. [PubMed: 12324553].
  • 12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65. [PubMed: 11583749].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments